EXPLAINED: 9 | Rare Historical Photos

Why Are Torrid Holdings (CURV) Shares Falling After Hours?

Torrid Holdings Inc. (NYSE:CURV) shares fell 14.5% to $1.12 in after-hours trading on Wednesday after the retailer reported its third-quarter fiscal results.

Benzinga · Dec 4, 2025

These Healthcare Stocks Just Exploded In Momentum — Investors Are Taking Notice

In the pulsating world of healthcare stocks, Elekta Inc. (OTC:EKTAY) has distinguished itself this week with a staggering 129% surge in its momentum score, leaping from 19.90 to 45.67. Elekta, a renowned manufacturer of medical equipment, found its stock trading at $5.86 on Wednesday, unmoved from the previous day’s close but comfortably…

Benzinga · Dec 3, 2025

Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza

William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.

Benzinga · Dec 3, 2025

Illegal weight-loss drugs being sold in UK by firms with high Trustpilot scores

Exclusive: Guardian investigation finds unlicensed jabs offered as experts call for more online regulation

The Guardian - UK · Nov 30, 2025

Weight loss drugs go from niche to mainstream

New pricing deals and aggressive marketing are transforming GLP-1s.

Axios · Nov 29, 2025

Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026

The U.S. Food Drug Administration (FDA) on Tuesday extended review for Ascendis Pharma A/S‘ (NASDAQ:ASND) New Drug Application (NDA) for TransCon CNP (navepegritide) for children with achondroplasia.

Benzinga · Nov 28, 2025

Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

Shares of Heartbeam Inc (NASDAQ:BEAT) rose sharply in pre-market trading after announcing its regulatory strategy following the Food and Drug Administration’s Not Substantially Equivalent (NSE) decision on its 12-lead Electrocardiogram Synthesis Software.

Benzinga · Nov 28, 2025

BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review

BiomX Inc. (NYSE:PHGE) on Tuesday announced that the U.S. Food and Drug Administration (FDA) is continuing its evaluation of the nebulizer device used for drug administration in the company's Phase 2b trial of BX004 in cystic fibrosis patients.

Benzinga · Nov 26, 2025

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Valneva SE (NASDAQ:VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.

Benzinga · Nov 26, 2025

Trump administration says lower prices for 15 Medicare drugs will save taxpayers billions

The Trump administration says pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations and that it's expected to produce billions in savings for older adults

The Independent UK · Nov 26, 2025